XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 160 filers reported holding XENON PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.16 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $25,675,988 | -11.3% | 751,639 | 0.0% | 0.15% | -11.4% |
Q2 2023 | $28,938,102 | +7.6% | 751,639 | 0.0% | 0.17% | +14.4% |
Q1 2023 | $26,901,160 | -9.2% | 751,639 | 0.0% | 0.15% | -18.0% |
Q4 2022 | $29,637,126 | +9.2% | 751,639 | 0.0% | 0.18% | 0.0% |
Q3 2022 | $27,134,000 | +18.7% | 751,639 | 0.0% | 0.18% | +36.9% |
Q2 2022 | $22,865,000 | -0.5% | 751,639 | 0.0% | 0.13% | -1.5% |
Q1 2022 | $22,978,000 | -2.1% | 751,639 | 0.0% | 0.13% | +15.8% |
Q4 2021 | $23,481,000 | +104.4% | 751,639 | 0.0% | 0.11% | +128.0% |
Q3 2021 | $11,485,000 | -17.9% | 751,639 | 0.0% | 0.05% | -18.0% |
Q2 2021 | $13,996,000 | +4.0% | 751,639 | 0.0% | 0.06% | +5.2% |
Q1 2021 | $13,454,000 | +27.3% | 751,639 | +9.3% | 0.06% | +45.0% |
Q4 2020 | $10,572,000 | +25.6% | 687,386 | -9.6% | 0.04% | +17.6% |
Q3 2020 | $8,417,000 | -16.0% | 760,308 | -4.9% | 0.03% | -22.7% |
Q2 2020 | $10,021,000 | – | 799,102 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 266,961 | $9,119,388 | 10.70% |
COMMODORE CAPITAL LP | 1,845,000 | $63,025,200 | 7.37% |
TLS Advisors LLC | 32,956 | $1,126 | 4.56% |
Altium Capital Management LP | 228,000 | $7,788,480 | 4.06% |
Paradigm Biocapital Advisors LP | 1,491,835 | $50,961,084 | 3.46% |
GREAT POINT PARTNERS LLC | 500,001 | $17,080,034 | 3.11% |
DAFNA Capital Management LLC | 280,538 | $9,583,178 | 2.98% |
Nan Fung Group Holdings Ltd | 106,680 | $3,644,189 | 2.95% |
Affinity Asset Advisors, LLC | 300,438 | $10,262,962 | 2.89% |
Avoro Capital Advisors LLC | 4,900,000 | $167,384,000 | 2.61% |